July 2026– date –
-
REPROCELL Unveils StemEdit Hypoimmune iPSCs with HLA Knockout, Accelerating Development of Off-the-Shelf Cell Therapies
REPROCELL (Blog) Japan Overview REPROCELL has announced the launch of its StemEdit hypoimmune iPSC lines, featuring HLA knockout through high-efficiency genome editing and regulatory-compliant cell lines. This technology aims to mitigate... -
Fate Therapeutics Secures FDA IND Clearance for FT839, a Dual iPSC-Derived CAR T-Cell Candidate, with Phase 1/2a Trial Targeting Autoimmune Diseases and Hematologic Malignancies to Commence in H2 2026
GlobeNewswire USA Overview Fate Therapeutics announced FDA IND clearance for FT839, its iPSC-derived dual CAR T-cell product candidate. FT839 is designed to simultaneously target CD19 and CD38, aiming for comprehensive treatment across a... -
Fate Therapeutics’ Off-the-Shelf iPSC-Derived CAR T-Cell Therapy FT819 Shows Promising Early Clinical Data in Treatment-Resistant Systemic Sclerosis
EurekAlert! USA Overview New preliminary clinical data for Fate Therapeutics' off-the-shelf iPSC-derived CAR T-cell therapy, FT819, was presented at ISSCR 2026, targeting patients with treatment-resistant systemic sclerosis. As part of a... -
Phase 1/2a Trial of Autologous iPSC-Derived Dopaminergic Progenitors for Parkinson’s Shows Positive 12-Month Interim Results in 8 Patients, Demonstrating Favorable Safety and Functional Improvement
International Society for Stem Cell Research USA Overview Interim clinical results from the first Phase 1/2a trial of autologous iPSC-derived dopaminergic progenitor cells for Parkinson's Disease were presented at ISSCR 2026, showing fav... -
Landmark Phase 1b/2a REGEN4HD Trial for Huntington’s Disease with Pluripotent Stem Cell-Derived Neural Stem Cells Unveiled at ISSCR 2026
International Society for Stem Cell Research International Overview The first clinical trial (Phase 1b/2a REGEN4HD study) of pluripotent stem cell-derived neural stem cells for Huntington's Disease was highlighted at the ISSCR 2026 annua... -
Databricks Secures Strategic Funding Round at $188 Billion Valuation to Accelerate AI Strategy, Including Unity AI Gateway and Genie
Databricks USA Overview Databricks announced a strategic funding round at an astounding $188 billion valuation, led by existing investor Coatue. This new capital will primarily accelerate the company's AI strategy, focusing on key produc... -
BandLab Acquires Fully Licensed AI-Powered Music Studio Aiode to Strengthen AI-Driven Music Creation and Licensing
M&A Today UK Overview BandLab has acquired Aiode, a fully licensed AI-powered music studio. This acquisition is part of a trend of M&A activity in the AI sector, as companies look to capitalize on the technology's success. By integra... -
NetApp Acquires AI Data Infrastructure Firm DataPelago to Eliminate Data Processing Bottlenecks for AI Workloads
Business Wire USA Overview NetApp acquired DataPelago, an AI data infrastructure company known for eliminating data processing bottlenecks for AI and analytics workloads. This acquisition expands NetApp's portfolio to enable GPU-accelera... -
Moonshot AI Releases 2.8 Trillion Parameter Kimi K3 MoE Model, NVIDIA Introduces 4B-Parameter Cosmos 3 Edge for On-Device AI
AI Weekly USA Overview Moonshot AI officially released Kimi K3, a 2.8-trillion-parameter Mixture-of-Experts model with a 1-million-token context window and native vision capabilities. In parallel, NVIDIA introduced Cosmos 3 Edge, a 4-bil... -
Chemomab and Scipher Medicine Merge to Advance AI-Guided Anti-CCL24 Antibody into Phase II Rheumatoid Arthritis Trial
PharmExec USA Overview Chemomab and Scipher Medicine have agreed to an all-stock merger to advance an anti-CCL24 antibody (CM-101) into an AI-guided Phase II rheumatoid arthritis trial. This integration combines their technologies and re...
